InvestorWire NewsRoom


InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference
March 5, 2024

InvestorNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces CEO Presentation at Upcoming Emerging Growth Conference

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, will be participating at tomorrow’s Emerging Growth Conference. The company announced that CEO Jim Joyce will give a live presentation; the presentation is slated to begin at 12 p.m. ET. According to the announcement, Joyce will provide an update on Sigyn Therapy(TM), the company’s novel blood-purification technology designed to address life-threatening conditions that are beyond the reach of drugs, and will review the company’s candidate products designed to enhance the benefit of chemotherapy and immunotherapeutic antibodies to treat cancer. The presentation will also include time for a Q&A. An archived copy of the webcast will be available following the presentation on the Emerging Growth YouTube channel.

To view the presentation, visit

To view the full press release, visit

About Sigyn Therapeutics Inc.

Sigyn Therapeutics is a development-stage, medical-technology company headquartered in San Diego, California. The company’s therapeutic candidates are designed to overcome clearly defined limitations in healthcare. These include the ImmunePrepplatform, ChemoPrep, ChemoPure and Sigyn Therapy. ImmunePrep is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for 9 of the top 15 best-selling cancer therapy drugs. ChemoPrep is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPureextracts off-target chemotherapy from the bloodstream to reduce treatment toxicity. Sigyn Therapy is a novel blood-purification technology being advanced to treat pathogen-associated inflammatory disorders. In vitro studies have demonstrated the ability of Sigyn Therapyto reduce the circulating prevalence of 12 pathogen and inflammatory-disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include community-acquired pneumonia, endotoxemia, drug-resistant viral and bacterial infections, endotoxemia and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. For more information, visit the company’s website at

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at 

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published:

Los Angeles, CA
310.299.1717 Office
[email protected]

InvestorWire is powered by IBN

Recent NewsBreaks

NewsBreaks Categories

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(862) 930-1404

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).